Drugs / PRI-724
PRI-724
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02195440 | Aug 2014 → Mar 2017 | hepatitis C induced liver cirrhosis | Komagome Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01764477 | Apr 2013 → Oct 2015 | pancreatic adenocarcinoma | Prism Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01302405 | Feb 2011 → Jan 2015 | cancer | Prism Pharma Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT03620474 | Jul 2018 → Jul 2021 | cirrhosis of liver, hepatitis B virus infection, hepatitis C virus infection | Kiminori Kimura, MD | Completed | Missed primary |
| Phase 1/2 | NCT01606579 | Jul 2012 → Dec 2016 | acute myeloid leukemia, chronic myeloid leukemia | Prism Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07681089 | Sep 2026 → Nov 2027 expected | cirrhosis of liver | Kiminori Kimura, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06144086 | May 2024 → Mar 2025 | cirrhosis of liver | Kiminori Kimura, MD | Completed | No outcome recorded |
| Phase 2 | NCT02413853 | Nov 2015 → Nov 2017 | colorectal adenocarcinoma | University of Southern California | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRI-724 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02413853 ↗ |
| Known as | (S,S)-ICG-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297813 ↗ |
| Known as | Foscenvivint | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681089 ↗ |
| Action | Inhibit | “PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread(metastasize).” NCT01302405 ↗ |
| Modality | Small molecule | “PRI-724 is a small molecule antagonist” NCT01764477 ↗ |
| Route | Intravenous | “administered as a 7-day CIV intravenous infusion” NCT01302405 ↗ |